Clinical correlates of mitochondrial function in Huntington's disease muscle

Movement Disorders

Volumn 22, Issue 12, 2007, Pages 1715-1721

  Turner, Christopher ^a   Cooper, J Mark ^a   Schapira, Anthony H V ^a,b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Complex II III; Huntington's disease; Mitochondria; Muscle; UHDRS

Indexed keywords

CYTOCHROME C OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE);

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DISEASE COURSE; DISEASE DURATION; FEMALE; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; MALE; MITOCHONDRION; MOTOR PERFORMANCE; PRIORITY JOURNAL; RATING SCALE; RESPIRATORY CHAIN; RESPIRATORY FUNCTION; SCORING SYSTEM; SKELETAL MUSCLE;

ADULT; AGED; CASE-CONTROL STUDIES; ELECTRON TRANSPORT COMPLEX IV; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; MITOCHONDRIA; MULTIENZYME COMPLEXES; MUSCLE, SKELETAL; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; SPECTROPHOTOMETRY; SUCCINATE DEHYDROGENASE; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 35348941757     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21540     Document Type: Article

References (30)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
2. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997;90:537-548.
3. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997;277:1990-1993.
4. Brinkman RR, Mezei MM, Theilmann J, Almqvist E, Hayden MR. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 1997;60:1202-1210.
5. Bates G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet 2003;361:1642-1644.
6. Landles C, Bates GP. Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep 2004;5:958-963.
7. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, Cattaneo E. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001;293:493-498.
8. Hamilton JM, Wolfson T, Peavy GM, Jacobson MW, Corey-Bloom J. Rate and correlates of weight change in Huntington's disease. J Neurol Neurosurg Psychiatry 2004;75:209-212.
9. Schapira AH. Mitochondrial dysfunction in neurodegenerative disorders. Biochim Biophys Acta 1998;1366:225-233.
10. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 1996;39:385-389.
11. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 1997;41:646-653.
12. Saft C, Zange J, Andrich J, Muller K, Lindenberg K, Landwehrmeyer B, Vorgerd M, Kraus PH, Przuntek H, Schols L. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov Disord 2005;20:674-679.
13. Lodi R, Schapira AH, Manners D, Styles P, Wood NW, Taylor DJ, Warner TT. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol 2000;48:72-76.
14. Arenas J, Campos Y, Ribacoba R, Martin MA, Rubio JC, Ablanedo P, Cabello A. Complex I defect in muscle from patients with Huntington's disease. Ann Neurol 1998;43:397-400.
15. Sawa A, Wiegand GW, Cooper J, Margolis RL, Sharp AH, Lawler JF, Jr., Greenamyre JT, Snyder SH, Ross CA. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med 1999;5:1194-1198.
16. Seong IS, Ivanova E, Lee JM, Choo YS, Fossale E, Anderson M, Gusella JF, Laramie JM, Myers RH, Lesort M, MacDonald ME. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet 2005;14:2871-2880.
17. Siesling S, van Vugt JP, Zwinderman KA, Kieburtz K, Roos RA. Unified Huntington's disease rating scale: a follow up. Mov Disord 1998;13:915-919.
18. Sheehan DC, Hrapchak BB. Theory and practice of histotechnology. Battelle Press: Columbus; 1987.
19. Schapira AH, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark JB, Marsden CD. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 1990;55:2142-2145.
20. Bradley JL, Blake JC, Chamberlain S, Thomas PK, Cooper JM, Schapira AH. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum Mol Genet 2000;9:275-282.
21. Wiechelman KJ, Braun RD, Fitzpatrick JD. Investigation of the bicinchoninic acid protein assay: identification of the groups responsible for color formation. Anal Biochem 1988;175:231-237.
22. Jenkins BG, Rosas HD, Chen YC, Makabe T, Myers R, MacDonald M, Rosen BR, Beal MF, Koroshetz WJ. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology 1998;50:1357-1365.
23. Orth M, Cooper JM, Bates GP, Schapira AH. Inclusion formation in Huntington's disease R6/2 mouse muscle cultures. J Neurochem 2003;87:1-6.
24. Strand AD, Aragaki AK, Shaw D, Bird T, Holton J, Turner C, Tapscott SJ, Tabrizi SJ, Schapira AH, Kooperberg C, Olson JM. Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum Mol Genet 2005;14:1863-1876.
25. Coggan AR, Spina RJ, King DS, Rogers MA, Brown M, Nemeth PM, Holloszy JO. Histochemical and enzymatic comparison of the gastrocnemius muscle of young and elderly men and women. J Gerontol 1992;47:B71-B76.
26. Paulsen JS, Zhao H, Stout JC, Brinkman RR, Guttman M, Ross CA, Como P, Manning C, Hayden MR, Shoulson I; Huntington Study Group. Clinical markers of early disease in persons near onset of Huntington's disease. Neurology 2001;57:658-662.
27. Jackson MJ, Pye D, Palomero J. The production of reactive oxygen and nitrogen species by skeletal muscle. J Appl Physiol 2007;102:1664-1670.
28. Tabrizi SJ, Cleeter MWJ, Xuereb J, Taanman JW, Cooper JM, Schapira AHV. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann Neurol 1999;45:25-32.
29. Solans A,Zambrano A,Rodriguez M, Barrientos A. Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III. Hum Mol Genet 2006;15:3063-3081.
30. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001;57:397-404.